Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma

Neuropathology

Volumn 27, Issue 2, 2007, Pages 114-120

  Bruna, Jordi ^a   Brell, Marta ^b   Ferrer, Isidre ^c   Gimenez Bonafe, Pepita ^d   Tortosa, Avelina ^c,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Anaplastic meningioma; Atypical meningioma; Ki 67 labeling index; Prognosis; Tumor recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ANAPLASTIC MENINGIOMA; ARTICLE; ATYPICAL MENINGIOMA; CANCER SURVIVAL; CELL LABELING; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MALE; MENINGIOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGY; TUMOR CLASSIFICATION; TUMOR RECURRENCE; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34147094807     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2007.00750.x     Document Type: Article

References (20)

1. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK (eds). Pathology and Genetics of the Nervous System: World Health Organization Classification of Tumours. Lyon: IARC Press, 2000; 176-184.
2. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: An analysis of histologic parameters. Am J Surg Pathol 1997; 21: 1455-1465.
3. Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB, Rhoton AL. Benign meningiomas: Primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 1997; 39: 427-436.
4. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: A clinicopathological review. Neurosurgery 1993; 33: 955-963.
5. McCarthy BJ, Davis F, Freels S et al. Factors associated with survival in patients with meningioma. J Neurosurg 1998; 88: 831-839.
6. Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: A study of 71 surgical cases. J Neurosurg 1997; 86: 793-800.
7. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85: 2046-2056.
8. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D. The accuracy of meningioma grading: A 10-year retrospective audit. Neuropathol Appl Neurobiol 2005; 31: 141-149.
9. Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors. Hum Pathol 1998; 29: 1420-1427.
10. Amatya VJ, Takeshima Y, Sugiyama K et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 2001; 32: 970-975.
11. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225.
12. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurochem 1957; 20: 22-39.
13. Tortosa A, Vinolas N, Villa S et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003; 97: 1063-1071.
14. Kayaselcuk F, Zorludemir S, Bal N, Erdogan B, Erdogan S, Erman T. The expression of survivin and Ki-67 in meningiomas: Correlation with grade and clinical outcome. J Neurooncol 2004; 67: 209-214.
15. Moller ML, Braendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J Neurooncol 1997; 34: 241-246.
16. Nakaguchi H, Fujimaki T, Matsuno A et al. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer 1999; 85: 2249-2254.
17. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998; 82: 2262-2269.
18. Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien) 2004; 146: 37-44.
19. Takahashi JA, Ueba T, Hashimoto N, Nakashima Y, Katsuki N. The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg Neurol 2004; 61: 149-155.
20. Mahmood A, Qureshi NH, Malik GM. Intracranial meningiomas: Analysis of recurrence after surgical treatment. Acta Neurochir (Wien) 1994; 126: 53-58.